NFKB1 and metabolic dysfunction-associated steatohepatitis: On the contrary, treatment with BM-MSCs-EV (120 μg/kg) significantly decreased the cardiac levels of NF-κB, IL-6 and TNF-α by 33%, 33.7% and 27%, respectively, as compared to cardiotoxicity induced by NASH group (Figure 7).